SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum
GLD 387.39+0.5%Dec 9 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Pogeu Mahone
From: Julius Wong9/18/2024 7:58:18 AM
1 Recommendation  Read Replies (1) of 218304
 
Elon Musk’s Neuralink wins FDA breakthrough tag for Blindsight device

Sep. 18, 2024 7:45 AM ET
By: Dulan Lokuwithana, SA News Editor

JHVEPhoto

Elon Musk-owned neurotechnology firm Neuralink has received the U.S. FDA’s breakthrough device designation for its experimental brain implant, Blindsight, designed to restore vision.

With its breakthrough devices program, the agency expects to speed up the development and review of more innovative medical devices, helping developers accelerate their market access.

Among its benefits, manufacturers with breakthrough device designations can seek FDA-priority review for their regulatory submissions.

Musk, the CEO of EV maker Tesla ( TSLA) and space exploration company SpaceX ( SPACE), welcomed the FDA’s decision shortly after Neuralink announced the designation.

“The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see,” he said.

Neuralink has already treated two patients in its FDA-cleared PRIME study for its brain-computer interface (BCI), designed to help patients with neurological conditions control external devices, such as computers, only with their thoughts.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext